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Abstract 
The impact of PD-1 immune checkpoint therapy prompts exploration of other strategies to 
downregulate PD-1 for cancer therapy. We previously showed that the serine/threonine 
kinase, glycogen synthase kinase GSK-ĮȕLVDFHQWUDOUHJXODWRURI3'-1 transcription in 
CD8+ T cells.  Here, we show that the use of small molecule inhibitors of GSK-Įȕ*6.-3i) 
to reduce pcdc1 (PD-1) transcription and expression was as effective as anti-PD-1 and PDL-1 
blocking antibodies in the control of B16 melanoma, or EL4 lymphoma, in primary tumor and 
metastatic settings.  Further, the conditional genetic deletion of GSK-ĮȕUHGXFHG3'-1 
expression on CD8+ T cells, and limited B16 pulmonary metastasis to the same degree as 
PD-1 gene deficiency.  In each model, GSK-3i inhibited PD-1 expression on tumor infiltrating 
lymphocytes (TILs), while increasing Tbx21 (T-bet) transcription, and the expression of 
CD107a+ (LAMP1) and granzyme B (GZMB) on CD8+ T-cells.  Lastly, the adoptive transfer of 
T-cells treated ex vivo with a GSK-3 inhibitor delayed the onset of EL4 lymphoma growth to a 
similar extent as anti-PD-1 pre-treatment.  Overall, our findings show how GSK-3 inhibitors 
that downregulate PD-1 expression can enhance CD8+ T-cell function in cancer therapy to a 
similar degree as PD-1 blocking antibodies. 
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Introduction  
The co-receptor programmed cell death 1 (PD-1; PDCD1) is a member of the B7 gene family 
that negatively regulates T-cell function (1-3). PD-1 is expressed in response to T-cell activation and 
contributes to the exhaustion of CD8+ T-cells during chronic infections (4,5).  The co-receptor binds 
to ligands, programmed cell death ligand 1 and 2 (PD-L1/L2), on lymphoid and non-lymphoid cells 
(6-8).  Immune checkpoint blockade with anti-PD-1 or anti-PD-L1 has proven successful in the 
treatment of human cancers, either alone or in combination with anti-CTLA-4 (9,10).  PD-1 
expression on tumor-infiltrating CD8+ T-cells correlates with impaired effector cell function (2,11), 
while PD-L1 expression on tumors can facilitate escape from the host immune system (3), and can 
serve as a prognostic factor (12).  Recent evidence indicates that recovery of responses from anti-
PD-1 blockade depends on the related co-receptor (13-15). 
The nature of the intracellular signaling pathways that regulate PD-1 expression on T-cells 
has been the subject of much interest. Pdcd1 expression can be positively and negatively regulated 
by different transcription factors such as nuclear factor of activated T-cells (NFAT), Forkhead box 
protein O1 (FoxO1), Notch, activator protein 1 (AP1), and Blimp1 (B-lymphocyte maturation protein 
1) (16-19).  Despite this, the identity of the upstream signaling event(s) that control PD-1 expression 
has been unclear.  We and others previously showed that T-cells are activated by protein-tyrosine 
kinases p56lck and ZAP-70 (20,21).  p56lck binds to co-receptors CD4 and CD8 (22-24) and 
phosphorylates immune receptor activation motifs (ITAMs) needed for ZAP-70 recruitment to the 
TcR-CD3 complex (20,23,25). By contrast, glycogen synthase kinase 3 (GSK-3) is a 
serine/threonine kinase that is active in resting T-cells, and becomes inactivated with T-cell 
activation (26,27). Differentially regulated isoforms of GSK-ĮDQGȕdiffer in their N- and C-terminal 
sequences and can influence pathways initiated by diverse stimuli.  The inactivation of GSK-3 can 
be mediated by several upstream kinases including protein kinase B (PKB/AKT).  In CD4+ T-cells, 
GSK-3 promotes the exit of NFAT from the nucleus (28,29). TCR and CD28 ligation phosphorylates 
and inactivates GSK-3 (30-32), while expression of active GSK-ȕLQKLELWVWKHSUROLIHUDWLRQRI7-cells 
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(30).  Engagement of PKB/AKT and GSK-3 in T-cells operates independently of guanine nucleotide 
exchange factor VAV-1 (31). Clinical trials using GSK-3 inhibitors have been undertaken in the 
treatment of type II diabetes and various neurological disorders (27,33-35).  
Recently, we reported that the inactivation of GSK-ĮȕZLWKsmall interfering RNAs (siRNAs) 
and small molecule inhibitors (SMIs) specifically down-regulate PD-1 expression for enhanced CD8+ 
CTL function and clearance of viral infections (36). The approach has introduced the possibility that 
small molecule inhibitors of GSK-3 may be effective in the down-regulation of PD-1 in the treatment 
of cancer. Here, we show that small molecule inhibitors of GSK-3 are as effective as anti-PD-1 in 
the control of B16 melanoma and EL4 lymphoma growth in mice. Our findings demonstrate, for the 
first time, the successful application of a GSK-3 inhibitor for the down-regulation of PD-1 on T-cells 
in cancer immunotherapy.  
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Materials and Methods 
Mice and cells.  
C57/Bl6 mice were used alongside OT-1 Tg and Rag2 knockout mice. Spleen cells were 
treated with a hypotonic buffer with 0.15M NH4CL, 10mM KHCO3 and 0.1mM EDTA, pH 7.2 to 
eliminate red blood cells before suspension in RPMI 1640 medium supplemented with 10% FCS, 
50uM beta-mercaptoethanol, sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and 
streptomycin (GIBCO).  T cells were isolated from tumor infiltrating cells, spleen and lymph node 
samples by use of T cell purification columns (R&D Systems).  In some cases, whole lymphocyte 
samples were used for flow cytometry to determine PD-1 expression in other cell types.  Cells 
included B16 F10 melanoma and EL4 lymphoma cells (obtained from the ATCC).  Each cell line 
was grown to achieve adequate numbers for freezing, followed by repeated thawing for use in the 
described experiments. The length and time between thawing and use in experiments was on 
average 3-4 weeks. The cell lines were authenticated by means cell surface staining and flow 
cytometry for characteristic markers and by their growth properties as described in the literature. 
Cell cultures were occasionally tested for mycoplasma (last tested in 2011). The research was 
regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 
following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body 
(AWERB) Home Office UK PPL No. 70/7544. 
 
Antibodies and reagents.   
The following antibodies were used in experiments; Anti-CD3 (2C11), anti-PD-1 (CD279, J43) and 
anti-CTLA-4 (9H10) (BioXCell); PD-L1 (E1L3N; Cell Signaling Technology), anti-Granzyme B and 
anti-T-bet (Abcam plc); anti-GSK-Įȕ &' FORQH (++ FRXSOHG ),7& DQG PRXVH ,J*
FITC control (Biolegend); conjugated antibodies anti-&'ĮFORQH-6.7), anti-CD4 (clone, RM4±
5), CD44, CD62L, CD25, CD69 (ebioscience).  Carboxyfluorescein succinimidyl ester (CFSE) 
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antibodies alongside PE Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend) was used for 
viability and proliferation assays. GSK3 inhibitors SB415286 3-(3-chloro-4-hydroxyphenylamino)-4-
(2-nitrophenyl)-1H-pyrrole-2,5-dione and AZ1080 (Abcam plc). OVA257-264 peptide (Bachem Ag).  
 
Flow cytometry.   
Flow cytometry of antibody staining of surface receptors was conducted by suspending 106 cells in 
ȝO3%6DQGDGGLQJDQWLERG\IRUKUDWoC.  Cells were then washed twice in PBS and in 
some cases suspended in 100Pl PBS with secondary antibody for a further 1h at 4oC. Cell staining 
was analyzed on a BD FACS Calibur flow cytometer and by FlowJo software. For intracellular 
VWDLQLQJFHOOVZHUH¿[HGLQSDUDIRUPDldehyde (PFA), permeabilized with 0.3% saponin (Sigma±
Aldrich) and stained with the desired antibody in saponin containing PBS for 2hr at 4oC, followed by 
a secondary Ab incubation where primary antibodies were not conjugated. 
 
Quantitative real-time polymerase chain reaction (PCR).  
Single-strand cDNA was synthesized with an RT-3&5NLW4LDJHQDFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions. Reverse transcription was performed using the RNA polymerase chain reaction (PCR) 
core kit (Applied Biosystems). Quantitative real-time PCR used SYBR green technology (Roche) on 
cDNA generated from the reverse transcription of purified RNA. After preamplification (95°C for 2 
min), the PCRs were amplified for 40 cycles (95°C for 15s and 60°C for 60s) in a sequence 
detection system (PE Prism 7000; Perkin-Elmer Applied Biosystems). The exponential phase, linear 
phase and plateau phase of PCR amplification were carefully monitored to ensure a measurement 
of real time transcription (33). mRNA expression was normalized against GAPDH expression using 
the standard curve method. PD-1-FW, 5-CCGCCTTCTGTAATGGTTTGA-3; PD-1-RV, 5-
GGGCAGCTGTATGATCTGGAA-3; Tbet-FW, 5-GATCGTCCTGCAGTCTCTCC-3; Tbet-RW, 5-
AACTGTGTTCCCGAGGT GTC-3; GAPDH-FW, 5-CAACAGCAACTCCCACTCTTC-3; GAPDH- 
RW, 5- GGTCCAGGGTT TCTTACTCCTT-3 
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Melanoma lung tumor establishment in wild type mice.   
B16 melanoma cells (2 x 105 taken from the log phase of in vitro growth) OVA-peptide pulsed or 
non-pulsed) were transferred intravenously into syngeneic C57BL/6J mice 10±12-weeks old. The 
lungs were removed 14 days after the transfer, and visible metastatic colonies on the lungs were 
counted.  In some cases, live imaging used B16 cells tagged with luciferase.  Mice were injected 
intraperitoneally with luciferin (2 ug per mouse), anaesthetized with isoflurane and scanned with an 
IVIS Lumina (Caliper Life Sciences). 
 
Microarray data 
There is no microarray data in the paper. 
 
Adoptive transfer of in vitro generated cytolytic T-cells (CTLs).   
In vitro generated T-cells were injected into mice with 7 day established EL4 tumors.  For this, OT-1 
CTLs were generated in vitro as previously described (36).  Primary mouse T cells were isolated 
using T-cell purification columns (R&D Systems).  OVA-specific CD8+ cytolytic T-cells were 
generated by incubating OT-I splenocytes with SIINFEKL peptide of OVA (OVA257-264) at 10 ng/mL 
for 5±7 days. Isolated T-cells (105 cells) were injected i.v. into mice with established EL4 tumors that 
had been intra-dermally injected into mice 7 days before cell transfer.  
 
Intradermal tumor establishment.   
EL4 or B16 tumor cells were taken from the log phase of in vitro growth (approx.. 70% confluency). 
In some cases where stated, cells were pulsed with OVA peptide for 1hr at 37oC). They were then 
washed and injected into mice (typically 3 x 106 cells for EL4 and 2 x 105 for B16 cells).  Tumors 
were clearly visible after 1 week and grew progressively in an encapsulated fashion.  Induced 
tumors were measured on a daily basis using a vernier caliper.  Tumors, spleens and lymph nodes 
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were harvested as indicated, either on day 10 or when the tumor reached a maximum diameter of 
12mm. PCR and flow cytometry were performed. 
 
Isolation of tumor infiltrating lymphocytes (TILs).   
Solid tumors or nodules from lungs were harvested from mice at the time indicated. Tissue was 
disrupted using a blade and then incubated in HBSS solution containing 200units/ml of collagenase 
at 37oC for 2 hrs. Tissue was then passed through a strainer and cells collected and layered onto 
ficoll before centrifugation. Tumor infiltrating cells were then collected from the lymphocyte layer.  
 
Statistical analysis.  
The mean and SE of each treatment group were calculated for all experiments. The number of 
samples is indicated in the figure legends.  Unpaired 6WXGHQW¶VWWHVWVRU$129$WHVWVZHUH
performed using the InStat 3.0 software (GraphPad).  In certain instances, statistics were done 
using 2-way ANOVA, or by non-parametric Mann Whitney at each time point. * P < 0.05, ** P < 
0.01, *** P < 0.001. 
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Results  
 
GSK-3 inhibits the growth of intravenous and intradermal injected tumors.  
 
 To assess whether the down-regulation of PD-1 by GSK-3 inhibition (GSK-3i) was effective in 
limiting tumor growth, B16 tumor cells were injected intravenously into C57/b6 mice with the GSK-3 
inhibitor SB415286 and/or anti-PD-1 (Fig. 1A).  The optimal dose of SB415286 and anti-PD-1 
established in this model was 200ug and 100ug/injection/mouse, respectively. The SMI or antibody 
was administered every two days following the injection of tumor, followed by a harvest of lungs on 
day 14 and an assessment of numbers of B16 nodules.  GSK-3 inhibitor SB415286 reduced the 
number of B16 spots from a mean of 145 to 60 (i.e. >55% inhibition).  This effect was comparable to 
anti-PD1 which showed a mean of 70 spots (i.e. >50% inhibition).  Further, the combination of 
SB415286 and anti-PD-1 had the same effect as SB415286 and anti-PD-1 individually (n=6).  Flow 
cytometry confirmed that GSK-3i reduced PD-1 expression on T-cells from the tumor (i.e. tumor 
infiltrating (TILs), spleen and draining lymph nodes (Fig. 1B). By contrast, no effect on the 
expression of other receptors such as CD3, CD8, CD44, CD62L, CD25 and CD69 was observed 
(Supplementary Fig. S1A), similar to previous results involving GSK3i in viral infection (36). GSK-
3i reduced pcdc1 (PD-1) transcription in T-cells from isolated spleen of tumor bearing mice (i.e. 3.7 
to 0.8), concurrent with an increase in Tbx21 (Tbet) transcription (i.e. 1.6 to 4.2) (Fig. 1C). 
Concurrent with reduced tumor growth, SB415286 treatment increased the % of CD8+ TILs 
expressing CD107a+ (Lamp1) and granzyme B (GZMB) (i.e. mean % of 14 to 23), indicative of an 
increased presence of CD8+ killer T-cells in the tumor mass (Fig. 1D). These data showed that the 
down-regulation of PD-1 with a small molecule inhibitor of GSK-3 can be as effective as anti-PD-1 in 
the control of B16 pulmonary metastasis in mice. 
 We also examined the effect of SB415286 doses on the growth of B16 cells tagged with 
luciferase (Fig. 1E). At day 14, mice were injected intraperitoneally with luciferin and scanned by 
IVIS Lumina imaging. SB416286 reduced the luciferase signal at 100 and 200ug/mouse, the dose 
of 200ug being more effective (left panels). In terms of T-cell subsets, both doses reduced PD-1 
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expression on the surface of CD8+ cells (right panels). By contrast, PD-1 expression was reduced to 
a lesser extent on CD3 negative NKp46+ NK cells. No reduction on NK cells was observed at 
100ug, despite the ability of this dose of drug to reduce tumor burden. Further, we found that PD-1 
expression on CD4+ T-cells, and CD4+ CD25+ FoxP3+ PD-1+ regulatory T-cells (TRegs) taken from 
tumors was unaffected. These data showed that GSK-3i preferentially down-regulated PD-1 on 
CD8+ T-cells, while having a lessor effect on NK cells and no obvious effect on CD4+ T-cells in the 
B16 tumor model.  In a comparison of injection frequency, more frequent injections of 200 or 400ug 
was optimal (Supplementary Figure S1B). 4 to 6 injections of each dose seemed optimal for tumor 
rejection and PD-1 down-regulation in vivo.  200ug was as effective as 400ug in these setting. 
 To assess the role of GSK-3 genetically, we next compared B16 tumor growth in GSK-3Į/ȕ 
conditional knock out mice relative to wild-type and PD-1 deficient mice (Pdcd1-/-). GSK-3Į/ȕ 
conditional knockout (GSK-3Į/ȕ-/-) mice were generated from a GSK-3 alpha flox/flox/beta flox/flox 
Lck Cre+ parental mice (parental line kindly provided by Dr. Jim Woodgett, U of Toronto). T-cells 
from conditional knockout GSK-3Į/ȕ-/- mice showed the expected reduction in PD-1 expression on 
CD8+ T-cells when assessed from mice injected with B16 cells and assayed on day 10 (Fig. 2A, left 
panel).  By contrast, no effect on PD-1 expression on CD4+ T-cells was noted, either in terms of cell 
number, or mean fluorescent intensity (MFI) (right panel). Secondly, B16 pulmonary metastasis was 
markedly reduced in GSK-3Į/ȕ-/-mice (Fig. 2B).  Intriguingly, the tumor growth in GSK-3Į/ȕ-/-mice 
was reduced to a similar extent as seen in Pdcd1-/- mice (i.e. from 110 spots to <10 in both sets of 
mice) (Fig. 2C).  Further, the injection of anti-PD-1 in GSK-3Į/ȕ-/- mice had no further effect on the 
number of nodules in lungs (Fig. 2B, upper inset). Conversely, the injection of SB415286, or 
another GSK-3 inhibitor, AZ1080 in Pdcd1-/- mice had no additional effect in reducing the number of 
nodules (Fig. 2C, upper inset). Overall, the data showed that GSK-3 inhibitor preferentially down-
regulated PD-1 expression on CD8+ T-cells and that the loss or inhibition of SB415286 and PD-1 in 
mice had the same effect in limiting B16 pulmonary metastasis.  This observation, combined with 
the finding that GSK-3 inhibitors had no further inhibition of tumor growth in Pdcd1-/- mice, and that 
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anti-PD-1 had no further effect on tumor growth in GSK-3Į/ȕ-/-mice supported the notion that GSK-
3 inhibition operated to limit tumor growth primarily via the down-regulation of anti-PD-1.   
 To further exclude that SB415286 had a direct effect on tumor cells, the SMI was injected into 
Rag2-/- mice (missing B and T-cells) with the B16 tumor (Fig. 2D). Under this condition, SB415286 
had no effect on limiting tumor growth. In addition, carboxyfluorescein succinimidyl ester (CFSE) 
labelled B16 cells were co-cultured of SB415286 in vitro over 5 days and assessed for differences. 
SB415286 had no obvious effect on the growth of B16 cells (Supplementary Fig. S2).  Taken 
together, these data was most consistent with the interpretation that protective effects of GSK-3i 
was due primarily to an effect on CD8+ T-cells.  
 We next also assessed whether the SMI SB415286 could affect PD-1 expression on human 
T-cells (Supplementary Fig. S3). Human CD4+ CD8+ T cells isolated from human peripheral blood 
were stimulated with anti-CD3/CD28 for 72hs prior to resting overnight and then incubated with 
SB415286 for various times and stained by flow cytometry for PD-1 expression. The SMI reduced 
the % of cells expressing PD-1 by >55% and the mean fluorescent intensity (MFI) for expression by 
>65% for cells when assayed at 48 hours (left upper and lower panels). Lesser inhibition was also 
apparent at >96 hours. See examples in right panels at 10min, 24 and 48 hours (right panel). As a 
control, the expression of CD3, CD4 and CD8 was unaffected. These data confirm that GSK-3i can 
be used to down-regulate PD-1 on CD3+CD8+ human T-cells. 
SB415286 and anti-PD-1 had similar effects on the growth of more established B16 
pulmonary metastases in mice (Fig. 3A). B16 tumor cells were injected intravenously and left for 7 
days before beginning treatment.  Lungs were harvested on day 19, and assessed for B16 nodules.  
Due to the extended time, non-treated animals showed larger nodules than seen in the previous 
experiments.  Despite this, injection of mice with either SB415286 and anti-PD-1 greatly reduced 
the number of nodules from 135 to 5-20. Both reagents also reduced the size of the remaining 
nodules from a mean of 3 to 0.05mm in diameter.  Further, the combined injection of SB415286 and 
anti-PD-1 reduced the number of spots to the same extent as each individual treatment (i.e. 5-10).  
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As a control, qPCR measurements confirmed the reduction in pcdc1 transcription, with a concurrent 
increase in Tbx21 transcription in splenic T-cells (Fig. 3B).  This reduction in PD-1 expression was 
confirmed by flow cytometry where we observed that SB415286 or combined therapy reduced PD-1 
expression in T-cells from spleen and TILs (Fig. 3C).  Further, this reduction in expression 
correlated with an increase in Lamp1 and GZMB expressing CD8+ TILs (Fig. 3D).   
We next investigated whether GSK-3 inactivation was also as effective as anti-PD-1 
checkpoint blockade in the control of the growth of solid B16 tumors.  For this, B16 cells were 
injected intra-dermally, followed by intra-peritoneal injections of either SB415286 or anti-PD-1 (Fig. 
4A).  We found that SB415286, anti-PD-1 and the combination slowed tumor growth such that 
10mm sized tumors were not seen until days 19-22, rather than day 14 in untreated mice. Further, 
SB415286 or anti-PD-1 increased overall survival to the same general extent, as seen in the 
Kaplan-Meier survival plot with a 40-50% survival at day 30 (Fig. 4B). As a control, qPCR of 
isolated spleen T-cells showed a marked decrease in pdcd1 transcription, while increasing the 
transcription of Tbx21 (Fig. 4C). Flow cytometry also showed a decrease in PD-1 expression in T-
cells from the spleen and extracted TILs (n=5) (Fig. 4D). Reduced Pdcd1 and increased Tbx21 
transcription was also observed in TILs (Fig. 4E).  Lastly, both SB415286 and combination therapy 
increased the numbers of CD107a+GZMB+CD8+ cells indicative of the increased presence of more 
effective killer T-cells (Fig. 4F).  There was no significant difference between the number of 
CD107a+GZMB+CD8+ cells with SB415286 versus SB415286 and anti-PD-1.  
We also assessed the effect of GSK-3 inactivation on immune cell rejection of another tumor 
model, EL4 lymphoma cells (Fig. 5). Priming of OT-1 OVA-specific T cells with SIINFEKL peptide of 
OVA (OVA257-264) produces a specific CTL response against tumor targets (37).  EL4 cells were pre-
treated with 0, 2, 5 and 10ug of OVA peptide, and washed, prior to injection. EL4 cells not exposed 
to peptide were injected into the left flank of OT-1 Tg mice, while those exposed to peptide were 
injected into the right flank.  SB415286 was injected intra-peritoneally on day 0, and tumor growth 
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was then monitored over 10 days before harvesting (Fig. 5A, upper panel).  Tumor size was 
reduced especially with 5 and 10ug OVA peptide; however, tumors were still evident at all peptide 
concentrations (lower panels). By contrast, in 4/7 experiments, SB415286 treatment resulted in a 
complete loss of tumor mass at all peptide concentrations in > 80% of mice. This remarkable tumor 
clearance was observed in mice of different ages, 4-6 weeks (Supplementary Fig. S4A), 6-10 
weeks (Supplementary Fig. S4B) and 6 months (Supplementary Fig. S4C). As a control, real 
time PCR of splenic T-cells confirmed SB415286 in vivo injection inhibited pcdc1 transcription, while 
increasing Tbx21 transcription (Fig. 5B).  Flow cytometry staining of cells with anti-PD-1 also 
confirmed the reduction in co-receptor expression. In experiments where the tumors were not 
eliminated by SB415286 at all peptide concentrations, the drug and anti-PD-1 had similar effects 
(Fig. 5C). At 5ug/ml OVA, untreated mice carried tumors of 5mm by day 14, while SB415286, anti-
PD-1, or the combination, delayed the appearance of this sized tumor until day 20-22. Similarly, in 
the case of mouse survival, at 2ug/ml OVA peptide, the SMI SB415286, anti-PD-1 and combination 
therapy increased survival from 17 to 24-26 days as seen by the Kaplan-Meier survival plot (lower 
panel). At 5ug/ml OVA, SB415286, anti-PD-1 and combination therapy increased survival from 21 to 
30-31 days. At 10ug/ml OVA peptide, SB415286 and anti-PD-1 completely protected against death, 
compared to day 25 for untreated mice. As an additional control, flow cytometric analysis of 
intracellular/surface stained cells showed that SB415286 treatment did not affect the expression of 
other markers (i.e. other than PD-1) such as CD44, CD4, FasL, FoxP3, CD152 (CTLA-4) and CD25 
(Supplementary Fig. S5). 
In another approach, we assessed PD-1 blockade using a blocking antibody to the PD-1 
ligand (PD-L1) (Fig. 5D).  SB415286, anti-PDL-1 and anti-PD-1 delayed the onset of EL-4 tumor 
growth at 5ug OVA peptide from an onset of growth from day 10 to 20-21 (upper left panel). At 10ug 
OVA, SB415286, anti-PDL-1 and anti-PD-1 completed eradicated the presence of tumors (upper 
right panel). Again, as a control with 5ug peptide, SB415286 markedly reduced in pdcd1 
Research. 
on October 24, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 20, 2017; DOI: 10.1158/0008-5472.CAN-17-0491 
 14 
transcription while increasing Tbet expression.  These studies showed SB415286, anti-PDL-1 and 
anti-PD-1 were remarkably similar in delaying the onset of tumor growth.  
We then compared the effect of GSK-3 inactivation versus anti-PD-1 on EL4 solid tumors in 
the absence of OVA peptide (Fig. 6). This required co-injections of SB415286 and/or anti-PD-1 as 
depicted (Fig. 6A) and an assessment of tumor growth over a longer period of 40 days.  EL4 tumors 
grew to 10mm by day 5 in untreated mice, which was prolonged to day 12 in SB41528 and anti-PD-
1-treated mice (lower panel).  The tumor completely regressed in one to three mice by day 18 with 
anti-PD-1, or the combination of SB41528 and anti-PD-1. The cooperative effect of combination 
therapy was also reflected in survival (Fig. 6B).  While untreated mice died by 11 days, 50% of mice 
on combined therapy remained alive by 40 days as shown in the Kaplan-Meier survival plot.  Flow 
cytometry of T-cells isolated from the spleens, draining lymph nodes and TILs demonstrated lower 
expression levels of PD-1 (Fig. 6C). This was confirmed with PCR demonstrating a reduction in 
Pdcd1 and an increase in Tbx21(Fig. 6D).  
To determine the duration of the effect of SB415286, PD-1 expression was monitored in mice 
co-injected with EL-4 tumors and a single injection of the drug (Supplementary Fig. S6). Mice were 
sacrificed at various times and PD-1 expression on spleen CD3+CD8+ T-cells was assessed by 
flow cytometry. The effects on PD-1 expression on CD3+CD8+ T-cells was sustained until 7-10 
days (i.e. 57% suppression at day 5; 42% at day 7) with expression returning to control levels from 
day 10-14 (i.e. 22% suppression at day 10 and 7% at day 14). These data indicate that the effects 
of SB415286 was sustained for over 7-10 days. 
Lastly, we tested whether pre-treatment of T-cells ex vivo with SB415286 provided protection 
(Fig.  7). EL4 cells were intra-dermally injected into mice for 7 days followed by the transfer of OT-1 
CTLs that had been cultured in vitro for 7 days in the absence or presence of OVA peptide plus the 
SMI SB415286 or anti-PD-1. The transfer of cells without any SB415286 or anti-PD-1 pre-treatment 
delayed the onset of growth at all peptide concentrations (Fig. 7A). However, pre-treatment with 
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SB415286, anti-PD-1 and in combination further slowed tumor growth. At 5ug Ova, each treatment 
delayed the onset of tumor growth until days 19-21. Further, tumors attained a diameter of 8mm by 
day 16 and at days 25-27 with SB415286, anti-PD-1 or combined therapy. In this instance, the 
effect of SB415286 was the same as anti-PD-1. Pre-cultured T-cells (prior to adoptive transfer) 
showed the expected decrease in pcdc1 transcription while increasing the transcription of Tbx21 
(Fig. 7B). Flow cytometry prior to transfer confirmed the reduction in PD-1 expression at different 
OVA concentrations (Fig. 7C). These data showed that the efficacy of GSK-3 inhibition was the 
result of a direct effect on T-cells, and that the pre-treatment of T-cells ex vivo with either anti-PD-1 
or SB415286 provided protection against tumor growth. 
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Discussion 
 Immune checkpoint blockade with anti-PD-1 or anti-PD-L1 has proven to be a highly 
promising treatment of human cancers, either alone or in combination with other reagents such as 
anti-CTLA-4 (2,9,10). However, only a minority of patients is responsive to this therapy, and there is 
a need to find alternate ways to complement present approaches. We previously showed that the 
kinase GSK-Įȕ is a central regulator of PD-1 expression and that small molecule inhibitors of 
GSK-3 (GSK3i) are effective in promoting viral clearance (33).  In this paper, we have shown that 
GSK-3i inhibition of pcdc1 (PD-1) transcription with a small molecule inhibitor (i.e. SB415286) is as 
effective as anti-PD-1 and PDL-1 blocking antibodies in the control of B16 and EL-4 tumor growth.  
Our findings identify a potential alternate approach using small molecule inhibition of PD-1 
expression in cancer therapy. 
 Our findings showed that GSK-3 inhibition with SMI treatment operates primarily via a 
reduction in PD-1 expression on the CD8+ T-cells. As in the case of drug inhibition of PD-1 
transcription, GSK-Įȕ-/- T-cells showed a reduction in PD-1 expression, while B16 pulmonary 
metastasis was reduced to a similar extent in Pdcd-/- and GSK-Įȕ-/- mice. In each model, GSK-3i 
inhibited Pdcd1 transcription and PD-1 expression on tumor infiltrating T-cells (TILs), while 
increasing Tbx21 (Tbet) transcription and the presence of CD8+ TILs expressing CD107a+ (LAMP1) 
and granzyme B (GZMB).  Despite this, it is also important to note that GSK-3 is likely to affect other 
aspects of T-cell function in an PD-1 independent fashion. We showed that the enzyme up-
regulates T-bet expression (36) which regulates the expression of numerous other genes such as 
GZMB and IFNJ1 (38). GSK-3i may eventually be found to alter the expression of other receptors 
and mediators and provide a potential advantage over anti-PD-1 blockade.  However, in the context 
of the models examined to date, the down-regulatory effect on PD1 plays a central role in 
generating anti-tumor immunity. 
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 The role of the immune system in providing protective immunity via GSK-3 was also seen in 
conditionally deleted GSK-Įȕ-/- mice.  Intriguingly, GSK-3 inactivation by gene ablation, or 
exposure to SMIs, preferentially reduced PD-1 expression on CD8+ T-cells.  Expression on CD4+ T-
cells, and CD4+ CD25+ FoxP3+ PD-1+ regulatory T-cells (Tregs) from tumors was unaffected.  
Although NK cells play key roles in eliminating B16 tumors (39-42), PD-1 expression was less 
affected on this subset than on CD8+ T-cells.  Further, at the lower SMI dose of 100ug, reduced 
PD-1 expression on NKp46+ NK cells was not observed, despite the protective effect of the reagent 
on B16 tumor growth.  At a higher dose, some reduction in PD-1 expression was observed, but to a 
lesser extent than seen on CD8+ T-cells. Further, SB415286 had no effect on B16 pulmonary 
metastasis in Rag2-/- mice which express NK cells.  Therefore, while we do exclude an effect on NK 
mediated killing of tumors (42), the anti-tumor effect of GS3i in our model was primarily due to an 
effect on CD8+ T-cells.  This latter observation also argued against a direct effect of the SMI on 
tumor growth. This lack of a direct effect of SMIs on tumors was supported by the absence of an 
effect of SB415286 on the in vitro growth of B16 cells.  
In addition to effects on B16 cells, GSK-3 inhibition, anti-PD-1 and anti-PDL-1 had similar 
effects on EL4 lymphoma solid tumor growth. In most mice, SB415286 treatment eradicated tumors, 
while in other mice, depending on the concentration of OVA peptide, the SMI delayed the onset of 
growth by 20-22 days.  GSK-3 inhibition, anti-PD-1 or anti-PDL-1 delayed tumor growth to the same 
extent.  Further, the combination of SB415286 and anti-PD-1 had the same effect as monotherapy.  
Occasionally, we observed some cooperation between anti-PD-1 and GSK-3i in the EL4 model, and 
therefore, we cannot exclude that future work will show cooperativity dependent on the tumor 
model.  
Lastly, we found that the ex vivo pre-treatment of CTLs followed by adoptive cell transfer was 
effective in the control of tumor growth.  As in the other models, SB415286 and anti-PD-1 delayed 
the onset of growth to the same extent. This experiment confirmed that the protective effect of GSK-
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3 on tumor growth was due to an effect on the function of T-cells.  Combination therapy did not 
provide an obvious improvement, supporting the notion that SB415286 was acting to inhibit tumor 
growth primarily by down-regulating the expression of PD-1.  GSK-3 SMIs may therefore have 
application to cell therapy, potentially to improve chimeric antigen receptor (CAR) therapy (43).   
Overall, there are potential advantages and disadvantages to the use of the GSK-3 SMI 
versus anti-PD-1 antibody therapies. Anti-PD-1 therapy is expensive and associated with adverse 
effects such as fatigue, rash and possible autoimmune complications such as colitis. Although we 
cannot exclude these inflammatory effects with the use of GSK-3 inhibitors, we have seen no 
evidence of autoimmunity with SMIs or in the GSK-3Į/ȕ-/- mice over 2 years.  Further, the use of 
many GSK-3 inhibitors is no longer restricted by patent coverage (27), and SMI inhibition offers the 
advantage of more accurate dosing, lower cost and the potential of oral administration. Importantly, 
PD-1 expression on both murine and human T-cells were down-regulated by GSK-3i.  
The potential disadvantage of GSK-3 inactivation is a possible direct effect on the function of 
other host cells or the tumor itself. However, lithium chloride, an inhibitor of GSK-3, has been used 
for decades for the treatment of bipolar disease without a reported increase in tumor frequency. The 
dose of SB415286 inhibitor (200ug per 20g mouse) in our study was roughly comparable to the 
dose of another inhibitor Tideglusib used in a phase 2 oral study (800mg in a 80kg patient) to treat 
progressive supranuclear palsy (35). Further, we showed that the effects of GSK-3 SMIs are 
durable such that a single dose injection of SB415286 down-regulated PD-1 for 10-14 days. 
Although, we failed to see any effect of SB415286 on the growth of B16 melanoma cells, GSK-3 
inhibition has been reported to directly inhibit the growth of multiple myeloma, neuroblastoma, 
hepatoma and prostate tumors (44-48). It is therefore possible that, in some instances, GSK-3 
inhibitors might directly inhibit the growth of some tumors. Despite these possibilities, the major 
effect of GSK-3i in our studies was amplify the ability of the immune system to react against tumor 
growth as shown by the effect of ex vivo treated T-cells in adoptive cell therapy as well as by the 
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elimination of tumors in mice where GSK-3Į/ȕ conditionally deleted in the T-cells.  Certain tumors 
can also impair proximal TCR signaling events as a form of immune avoidance (49,50). The 
inhibition of GSK-3 could potentially circumvent this impairment given that GSK-3 operates down-
stream of proximal signal mediators such as p56lck. Further work is needed to uncover the full range 
of down-stream effects that may be regulated by GSK-3 regulation in anti-tumor immunity. 
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Figures 
Figure 1. GSK-3 inhibition, anti-PD-1 and combination reduce pulmonary metastasis of B16 
melanoma to the same extent. (A) Schematic representation of treatment regime (left upper 
panel).  Histogram showing the number of lung spots per animal with or without the described 
treatment (right panel), photograph below shows 1 example of each group (n=6 mice per condition). 
(B) Flow cytometric profiles of PD-1 expression for T cells isolated from spleen, draining lymph 
nodes and tumor infiltrating lymph nodes (TILs) (data representative of 6 samples). (C) Quantitative 
real-time PCR of PD-1 and T-bet transcription of splenic T cells. (D) % of CD8+ cells expressing 
granzyme B of tumor infiltrating cells as determined by flow cytometry (n=6)**, P < 0.001. (E) Dose 
response of SB415286 on B16 melanoma. C57/bl6 mice were injected intravenously with luciferase 
tagged B16 melanoma cells and treated with doses of SB41586 as indicated. Luminescent images 
show B16 metastasis at day 14 and flow cytometric profiles to the right of each image show the 
level of PD1 expression on different cell subsets, taken from the spleen at day 14 (n=3).  
 
Figure 2. Pulmonary metastasis of B16 melanoma is reduced to the same extent in GSK-Įȕ
-/- and Pdcd-/- mice. (A) CD8+T-cells from GSK-Įȕ-/- mice show a decrease in PD-1 expression 
relative to CD8+T-cells from wild-type control mice (left) CD8+ T-cells (Right) CD4+ T-cells.  (B) 
GSK-Įȕ-/- enhanced clearance of lung melanoma. Upper inset: expanded abscissa range 
showing a lack of an effect of anti-PD-1 on numbers of nodules in GSK-Įȕ-/- mice (n=5 mice per 
condition). *, P < 0.05; **, P < 0.001; ns, no significant difference relative to controls. (C) Pdcd-/- 
mice show enhanced clearance of lung B16 melanoma. Upper right inset: expanded abscissa range 
showing a lack of an effect of GSK-3 inhibitors SB415286 and AZ1080 on numbers of B16 nodules 
in Pdcd-/- mice. (n=5 mice per condition). Panel shows a representative experiment.  *, P < 0.05; **, 
P < 0.001; ns, no significant difference relative to controls. (D) Inhibition of GSK-3 does not affect 
pulmonary metastasis of B16 melanoma in Rag2-/- mice. Left panel: photo of lungs harvested from 
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Rag2-/- mice 14 days after injection of B16 cells in the presence or absence of the injection of 6 
doses of 200Pg SB415286. Right panel: histogram shows number of spots from mice in left panel 
(n=3).    
 
Figure 3. GSK-3 inhibition and anti-PD-1 enhance clearance of established B16 tumors 
(A) Schematic representation of treatment regime (upper left panel). Histogram showing the number 
of lung spots per animal with or without the described treatment (right panel), Photograph below 
shows 1 example of each group. (n=6 mice per condition).  (B) Quantitative real-time PCR of PD-1 
and T-bet transcription of splenic T cells from animals used in (A) (n=5). *, P < 0.05; **, P < 0.001; 
ns, no significant difference relative to controls. (C) Flow cytometric profiles of PD-1 expression on T 
cells isolated from spleen and TILs (data representative of 5 samples). (D) % of CD8+ cells 
expressing granzyme B of tumor infiltrating cells as determined by flow cytometry (n=5)  
Figure 4. GSK-3 inhibition and anti-PD-1 inhibit growth of solid B16 tumors. (A) Schematic 
representation of treatment regime (upper panel); tumor growth curves (lower panels). Number in 
lower right corner represents how many mice (out of 3) from each treated condition were tumor free 
at the end of the study. (B) Survival curves of mice with and without treatment as shown (n=6; 
number of mice: 24). Panel shows a representative experiment. (C) Quantitative real-time PCR of 
splenic T-cells. (D) Flow cytometric profiles for T-cells isolated from draining lymph nodes and TILs 
(data representative of 5 samples). (E) Quantitative real-time PCR of tumor infiltrating lymphocytes.  
(F) % of CD8+ cells expressing CD107a/granzyme B (GZMB) of tumor infiltrating cells as 
determined by flow cytometry.  **P < 0.001; ns, no significant difference relative to controls.  
Figure 5. GSK-3 inhibition and anti-PD-1/PL1 attenuate growth to a similar extent of solid 
EL4-OVA tumors.  (A) GSK-3 inhibition enhances clearance of solid EL4-OVA tumors. (Top panel) 
Schematic representation of treatment regime for EL4 solid tumor model with different 
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concentrations of OVA peptide. Non-OVA pulsed EL4 cells were injected into the left flank and EL4-
OVA cells into the right flank.  (Middle panel) Photograph showing tumor growth after 10 days of 
OVA-pulsed EL4 tumor cells in OT-1 Tg mice with or without SB415286 injection (upper panel). 
(Lower panel) Tumor growth curves (n=6 mice per condition).  Panel shows a representative 
experiment. (B) Real time PCR of splenic T-cells confirmed SB415286 inhibition of PD-1 and Tbet 
transcription. Flow cytometric profile of anti-PD-1 staining of spleen T-cells. (C) SB415286 and anti-
PD-1 alone and in combination attenuate B16 cell growth (upper panels).  Lower panel: SB415286 
and anti-PD-1 alone and in combination increased mouse survival to the same degree.  2ug OVA 
peptide (lower left panel); 5ug OVA peptide (lower middle panel); 10ug/ml (lower right panel). 
Number in lower right corner represents how many mice (out of 6) were tumor free at the end of the 
study.   (D) SB415286, anti-PD-1 and anti-PD L-1 (PD-1 ligand) show a similar effect on the 
inhibition of EL4 tumor growth (upper panels). Left panel: effects in the presence of 5ug OVA 
peptide; Right panel: effects in the presence of 10ug OVA peptide. Number in lower right corner 
represents how many mice (out of 3) from each treated condition were tumor free at the end of the 
study.  Lower panel: Quantitative real-time PCR of PD-1 and T-bet transcription. 
 
Figure 6. GSK-3 inhibition and combined anti-PD-1 therapy slows solid EL4 tumor growth. 
(A) Schematic representation of treatment regime for EL4 solid tumor model without OVA-
presentation (upper panel). Tumor growth curves (lower panels) (n=6 mice per condition). Number 
in lower right corner represents how many mice (out of 6) were tumor free at the end of the study.  
(B) Survival curves. (C) Flow cytometric profiles of PD-1 expression, data representative of 5 
samples. (D) Quantitative real-time PCR of PD-1 and T-bet transcription (n=5). 
  
Figure 7. Ex vivo pre-treatment of T-cells with SB415286, anti-PD-1 or combination followed 
by adoptive therapy delayed the onset EL4-OVA tumor growth. (A) Regime of adoptive therapy 
Research. 
on October 24, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 20, 2017; DOI: 10.1158/0008-5472.CAN-17-0491 
 29 
(upper panel). Tumor growth curves (n=3; number of mice: >20) (lower panels). Panel shows a 
representative experiment. Number in lower right corner represents how many mice (out of 3) from 
each treated condition were tumor free at the end of the study. (B) Real time PCR of splenic T-cells 
prior to adoptive transfer confirmed SB415286 inhibition of PD-1 and Tbet transcription (upper 
panels). (C) Flow cytometric profiles of anti-PD-1 staining of spleen T-cells treated with different 
concentrations of OVA peptide prior to adoptive transfer. 
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